Skip to contentD
DiaMedica Therapeutics Inc.
D
DMACDiaMedica Therapeutics Inc. Released Aug 10, 2026, after the close
10-Q filed Aug 10, 2026, 41 days after period end · 0001437749-26-026792
Q2 2026 · 10-Q
Revenue—
Net Income-$10.14M-$10.14MN/M vs Q2 2025N/M vs Q1 2026 EPS, diluted
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DiaMedica Therapeutics Inc. · CIK 1401040 · Engraved from SEC EDGAR
—
Operating Income-$10,498,000N/M Operating Cash Flowderived-$8,114,000N/M Free Cash Flowderived-$8,117,000N/M ended Jun 30, 2026 · filed Aug 10, 2026 · 41 d after period end
+3.3% from the close of Aug 10, 2026 to the close of Aug 11, 2026, the first after the release.
after the close$6.65$6.87 Jul 20Aug 10Sep 1